Search Results

1 - 5 of 5 items :

  • "prostate cancer" x
  • Clinical Medicine, other x
Clear All

-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst . 2004;96:879-882. 7. Berenson JR, Hillner BE, Kyle RA, et al. American society of clinical oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol . 2002;20:3719-3736. 8. Delmas PD. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol . 2005;17:462-466. 9. Medical economics. Physicians’ Desk Reference. 57th ed. Montvale, NJ: Medical Economics

REFERENCES 1. Hatano K, Fujita S, Tsujimoto Y, et al. Rare case of the hyaline vascular type of Castlemans’s disease of the kidney. International Journal of Urology . 2007;14:1098-1100. 2. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer . 1956;9:822-830. 3. Guthrie PJ, Thomas JV, Peker D, Turkbey B, Rais-Bahrami S. Perivesical unicentric Castleman disease initially suspected to be metastatic prostate cancer. Urol Ann . 2016;8:245-248. 4. Vassos N, Raptis D, Lell M, et al. Intra-abdominal localized

, Costerton JW, Sedghizadeh PP. The role of microbial biofilms in osteonecrosis of the jaw associated with bisphosphonate therapy. Curr Osteoporos Rep . 2010;8:40-48. 11. Solomon DH, Mercer E, Woo SB, Avorn J, Schneeweiss S, Treister N. Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges. Osteoporosis International . 2013;24:237-244. 12. Walter C, Al-Nawas B, Grotz KA, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease

prior to coronary revascularisation? Heart Lung Circ . 2012;21:468-479. 30. Xi L, Rui X, Zhang B, Gao F. MRI tracking stem cells transplantation for coronary heart disease. Pak J Med Sci . 2014;30:899-903. 31. Sterenczak KA, Meier M, Glage S, et al. Longitudinal MRI contrast enhanced monitoring of early tumour development with manganese chloride (MnCl2) and superparamagnetic iron oxide nanoparticles (SPIOs) in a CT1258 based in vivo model of prostate cancer. BMC Cancer . 2012;12:284. 32. Guenoun J, Koning GA, Doeswijk G, et al. Cationic Gd-DTPA liposomes for highly

electrophoresis. Forensic Sci Int Genet Suppl Ser . 2013;4:e274-e275. 26. Kuner R, Brase JC, Sültmann H, Wuttig D: microRNA biomarkers in body fluids of prostate cancer patients. Methods . 2013;59:132-137. 27. Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. PLoS One . 2008;3:1-7. 28. Roth C, Rack B, Müller V, Janni W, Pantel K, Schwarzenbach H. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res . 2010;12:R90. 29. Guo Z, Maki M, Ding R, Yang Y, Zhang B, Xiong L. Genome